Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 571c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($5.71). Revenue for the quarter came in at $34.08 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Rambus launches DDR5 9600 server RDIMM chipset for AI workloads
• S&P downgrades Harley-Davidson to BB+ on margin concerns